GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Capex-to-Operating-Cash-Flow

NKGen Biotech (NKGen Biotech) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

NKGen Biotech's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $-4.03 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


NKGen Biotech Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for NKGen Biotech's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Capex-to-Operating-Cash-Flow Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
- - -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of NKGen Biotech's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, NKGen Biotech's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NKGen Biotech's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Capex-to-Operating-Cash-Flow falls into.



NKGen Biotech Capex-to-Operating-Cash-Flow Calculation

NKGen Biotech's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.048) / -21.948
=N/A

NKGen Biotech's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -4.034
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKGen Biotech  (NAS:NKGN) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


NKGen Biotech Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.